Heat shock protein 90 (HSP90) is a vital chaperone protein, regulating signaling pathways
and correcting misfolded proteins in cancer cells by interacting with oncogenic client …

The 90-kDa heat shock protein (Hsp90) is a molecular chaperone that ensures cellular
proteostasis by maintaining the folding, stabilization, activation, and degradation of over 400 …

Background Prognosis of advanced gastrointestinal stromal tumors (GIST) refractory to
tyrosine kinase inhibitors (TKIs) is poor. This randomized, placebo-controlled, phase III trial …

Chemotherapeutics occupy a pivotal role in the medication of different types of cancers, but
the prevalence and mortality rates of cancer remain high. The drug resistance and low …

Pimitespib (Jeselhy®) is an oral small molecule inhibitor of the α and β isoforms of heat
shock protein 90 (HSP90). HSP90α and HSP90β regulate the stability and activity of a …

In the past few decades, the development of heat shock protein 90 (Hsp90) inhibitors for
cancer treatment has not stopped. About twenty compounds have been evaluated in the …

Aberrant activation of the NLRP3 inflammasome is recognized to induce a chronic
inflammatory response in the liver, ultimately leading to hepatic fibrosis. HSP90 is suggested …

The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either
the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib, a KIT/PDGFRA tyrosine …

Sorafenib, a multikinase inhibitor, is a first-line treatment for advanced hepatocellular
carcinoma, but its long-term effectiveness is limited by the emergence of resistance …

Despite the effectiveness of imatinib, most gastrointestinal stromal tumors (GISTs) develop
resistance to the treatment, mainly due to the reactivation of KIT tyrosine kinase activity …